Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services CHARLESTOWN, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today shared that the U.S. Department of Health and Human Services (HHS) officially added Duchenne muscular dystrophy (Duchenne) to the Recommended Uniform Screening Panel (RUSP), the list of conditions recomme...
Frequency Electronics, Inc. Announces Second Quarter and Fiscal Year 2026 Financial Results MITCHEL FIELD, N.Y., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Frequency Electronics, Inc. (“FEI” or the “Company”) (NASDAQ-FEIM) is pleased to announce its financial results for the second quarter and fiscal year 2026. Revenue for the three and six months ended October 31, 2025, was approximately $17.1 million and $30.9 million, respectively, compared to $15.8 million and $30.9 million, respectively, reported for the same period of fiscal year 2025. Operating income for the three and six months ended Oct...
Frequency Electronics Announces Second Quarter Fiscal 2026 Financial Results Conference Call: Thursday, December 11, 2025, at 4:30 PM ET MITCHEL FIELD, N.Y., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Frequency Electronics, Inc. (NASDAQ: FEIM), will hold a conference call to discuss results for the second quarter of its fiscal year 2026, ended October 31, 2025, on Thursday, December 11, 2025, at 4:30 PM Eastern Time. This call is being webcast by Issuer Direct Corporation and can be accessed in the Investor Relations section of Frequency’s web site at . Investors and analysts may also access the...
Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum CHARLESTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it will present data from its next-generation, proprietary capsid AAV-SLB101 and its cardiac gene therapy pipeline at the Global CardioVascular Clinical Trialists (CVCT) Forum...
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CHARLESTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 23,284 restricted stock units (“RSUs”) to two newly hired employees. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s c...
Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia – SGT-212 has been granted FDA Rare Pediatric Disease and Fast Track designations – – SGT-212 is the only dual route gene therapy in development to treat Friedreich’s ataxia – – FALCON Phase 1b clinical trial participant screening underway – CHARLESTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and c...
A director at Harley-Davidson Inc sold 11,500 shares at 23.213USD and the significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
Frequency Electronics, Inc. Announces Contract Increase for Approximately $5 Million GARDEN GROVE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- FEI-Zyfer, Inc., a wholly-owned subsidiary of Frequency Electronics, Inc. (“FEI” or the “Company”) (NASDAQ-FEIM), a leading provider of precision timing and frequency control products, is pleased to announce the receipt of two follow-on change orders with a combined value of approximately $4.75M for on-going work on the development and manufacture of a customized version of our high-precision airborne time, synchronization, and frequency distribution...
Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101 - Non-exclusive license providing Solid’s proprietary, next-generation capsid, AAV-SLB101, to Andelyn Biosciences, a full-service cell and gene therapy Contract Development and Manufacturing Organization (CDMO) -- AAV-SLB101 has been generally well tolerated in the 23 participants dosed in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of a safety cutoff of October 31, 2025 - - Solid continues to expand collaborative efforts for AAV-SLB101 with over 30 agr...
Solid Biosciences to Participate at Upcoming Investor Conferences CHARLESTOWN, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: Jefferies Global Healthcare Conference in LondonBo Cumbo, President and CEO, and Gabriel Brooks, MD, Chief Medical Officer, will participate in a fireside chat on Tuesday, November 18, 2025, at 11:00 a.m. GMT (6:00 a.m. ET). Piper Sand...
Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy - Innovation Passport award facilitates accelerated time to market and helps expedite patient access to transformative new medicines - - New Innovative Licensing and Access Pathway (ILAP) designation provides unique, end-to-end regulatory access pathway for Solid to work directly with the UK’s National Health System (NHS), the UK Medicines and Healthcare products Regulatory Agency (MHRA) and health t...
Angi Inc. Earnings Release and Letter to Shareholders Available on Company’s Website DENVER, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Angi Inc. (NASDAQ: ANGI) posted its third quarter financial results and a letter to shareholders from CEO, Jeffrey Kip on the investor relations section of its website at ir.angi.com/quarterly-earnings. As announced previously, Angi Inc. will host a conference call to discuss the company’s third quarter results and to answer questions. The call will be held on Wednesday, November 5, 2025, at 8:30 a.m. ET. Jeffrey Kip, CEO and Andrew Russakoff, CFO will participate...
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CHARLESTOWN, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 26,550 restricted stock units (“RSUs”) to two newly hired employees. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s c...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.